Which has better valuation and earnings, IMMX or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is IMMX or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Rapport Therapeutics N/A -24.78% -23.44%

Does the media prefer IMMX or RAPP?

In the previous week, Rapport Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Rapport Therapeutics and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat Rapport Therapeutics' score of 0.58 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADMA or IMMX?

In the previous week, ADMA Biologics had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for ADMA Biologics and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat ADMA Biologics' score of 0.41 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, IMMX or AAPG?

Immix Biopharma has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Ascentage Pharma Group International $82.10M 20.39 -$177.71M N/A N/A

Is IMMX or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Ascentage Pharma Group International N/A N/A N/A

Does the media refer more to IMMX or AAPG?

In the previous week, Ascentage Pharma Group International had 4 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Ascentage Pharma Group International and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat Ascentage Pharma Group International's score of 0.27 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMMX or ZYME more profitable?

Immix Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Zymeworks -126.92% -37.97% -25.31%

Does the media refer more to IMMX or ZYME?

In the previous week, Zymeworks had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Zymeworks and 2 mentions for Immix Biopharma. Zymeworks' average media sentiment score of 0.93 beat Immix Biopharma's score of 0.86 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immix Biopharma (IMMX) Competitors

$8.61 +0.25 (+2.99%)

As of 03:04 PM Eastern

Compare

IMMX vs. RAPP, ADMA, AAPG, ZYME, and ANIP

Should you buy Immix Biopharma stock or one of its competitors? MarketBeat compares Immix Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immix Biopharma include Rapport Therapeutics (RAPP), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Zymeworks (ZYME), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.

How does Immix Biopharma compare to Rapport Therapeutics?

Immix Biopharma (NASDAQ:IMMX) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Immix Biopharma has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rapport Therapeutics' return on equity of -24.78% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Immix Biopharma currently has a consensus target price of $19.50, indicating a potential upside of 125.56%. Rapport Therapeutics has a consensus target price of $58.83, indicating a potential upside of 60.13%. Given Immix Biopharma's higher probable upside, equities research analysts clearly believe Immix Biopharma is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Rapport Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Rapport Therapeutics and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat Rapport Therapeutics' score of 0.58 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immix Biopharma and Rapport Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Immix Biopharma compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, ADMA Biologics had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for ADMA Biologics and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat ADMA Biologics' score of 0.41 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.51	$146.93M	$0.68	11.36
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

ADMA Biologics has a net margin of 32.43% compared to Immix Biopharma's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Immix Biopharma	N/A	-73.24%	-59.20%

ADMA Biologics currently has a consensus price target of $19.00, indicating a potential upside of 145.95%. Immix Biopharma has a consensus price target of $19.50, indicating a potential upside of 125.56%. Given ADMA Biologics' higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats Immix Biopharma on 11 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Ascentage Pharma Group International?

Immix Biopharma (NASDAQ:IMMX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ascentage Pharma Group International's return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Ascentage Pharma Group International	N/A	N/A	N/A

Immix Biopharma currently has a consensus price target of $19.50, indicating a potential upside of 125.56%. Ascentage Pharma Group International has a consensus price target of $46.67, indicating a potential upside of 160.13%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Immix Biopharma has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Ascentage Pharma Group International	$82.10M	20.39	-$177.71M	N/A	N/A

Immix Biopharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 4 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Ascentage Pharma Group International and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.86 beat Ascentage Pharma Group International's score of 0.27 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascentage Pharma Group International beats Immix Biopharma on 8 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Zymeworks?

Immix Biopharma (NASDAQ:IMMX) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Immix Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Immix Biopharma has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Zymeworks	$105.96M	16.54	-$81.13M	-$1.37	N/A

Immix Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Zymeworks	-126.92%	-37.97%	-25.31%

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immix Biopharma presently has a consensus target price of $19.50, suggesting a potential upside of 125.56%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 58.28%. Given Immix Biopharma's higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Zymeworks had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 4 mentions for Zymeworks and 2 mentions for Immix Biopharma. Zymeworks' average media sentiment score of 0.93 beat Immix Biopharma's score of 0.86 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zymeworks beats Immix Biopharma on 11 of the 16 factors compared between the two stocks.

How does Immix Biopharma compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Immix Biopharma had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 2 mentions for Immix Biopharma and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.14 beat Immix Biopharma's score of 0.86 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Immix Biopharma	Positive

ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ANI Pharmaceuticals has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$923.71M	1.85	$78.34M	$3.95	18.97
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

ANI Pharmaceuticals has a net margin of 9.98% compared to Immix Biopharma's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Immix Biopharma	N/A	-73.24%	-59.20%

ANI Pharmaceuticals presently has a consensus price target of $107.33, indicating a potential upside of 43.24%. Immix Biopharma has a consensus price target of $19.50, indicating a potential upside of 125.56%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ANI Pharmaceuticals beats Immix Biopharma on 12 of the 15 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$468.59M	$3.27B	$6.26B	$12.43B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-9.36	17.91	22.42	24.23
Price / Sales	N/A	322.86	548.01	125.38
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	4.88	6.59	9.82	6.71
Net Income	-$29.44M	$24.20M	$3.56B	$337.09M
7 Day Performance	-0.97%	-3.13%	-1.17%	0.63%
1 Month Performance	-7.04%	0.44%	3.71%	5.15%
1 Year Performance	309.72%	46.70%	27.28%	34.36%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	2.6183 of 5 stars	$8.61 +3.0%	$19.50 +126.5%	+221.5%	$468.53M	N/A	N/A	9
RAPP Rapport Therapeutics	3.3081 of 5 stars	$39.51 -0.5%	$58.83 +48.9%	+271.3%	$1.90B	N/A	N/A	N/A	Analyst Forecast
ADMA ADMA Biologics	4.7959 of 5 stars	$7.92 -2.8%	$19.00 +139.9%	-62.8%	$1.89B	$510.17M	11.65	530
AAPG Ascentage Pharma Group International	3.4935 of 5 stars	$20.57 +2.2%	$46.67 +126.8%	-26.8%	$1.88B	$82.10M	N/A	600
ZYME Zymeworks	2.5824 of 5 stars	$24.79 -2.4%	$38.00 +53.3%	N/A	$1.85B	$105.96M	N/A	460	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. RAPP, ADMA, AAPG, ZYME, and ANIP

How does Immix Biopharma compare to Rapport Therapeutics?

Summary

How does Immix Biopharma compare to ADMA Biologics?

Summary

How does Immix Biopharma compare to Ascentage Pharma Group International?

Summary

How does Immix Biopharma compare to Zymeworks?

Summary

How does Immix Biopharma compare to ANI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. RAPP, ADMA, AAPG, ZYME, and ANIP

How does Immix Biopharma compare to Rapport Therapeutics?

Which has more risk and volatility, IMMX or RAPP?

Do institutionals and insiders have more ownership in IMMX or RAPP?

Is IMMX or RAPP more profitable?

Which has better valuation and earnings, IMMX or RAPP?

Do analysts recommend IMMX or RAPP?

Does the media prefer IMMX or RAPP?

Summary

How does Immix Biopharma compare to ADMA Biologics?

Does the media favor ADMA or IMMX?

Which has more risk and volatility, ADMA or IMMX?

Which has stronger valuation and earnings, ADMA or IMMX?

Is ADMA or IMMX more profitable?

Do analysts prefer ADMA or IMMX?

Do insiders and institutionals believe in ADMA or IMMX?

Summary

How does Immix Biopharma compare to Ascentage Pharma Group International?

Do institutionals & insiders have more ownership in IMMX or AAPG?

Is IMMX or AAPG more profitable?

Do analysts rate IMMX or AAPG?

Which has better earnings and valuation, IMMX or AAPG?

Which has more volatility and risk, IMMX or AAPG?

Does the media refer more to IMMX or AAPG?

Summary

How does Immix Biopharma compare to Zymeworks?

Which has more risk & volatility, IMMX or ZYME?

Which has preferable valuation & earnings, IMMX or ZYME?

Is IMMX or ZYME more profitable?

Do institutionals & insiders hold more shares of IMMX or ZYME?

Do analysts prefer IMMX or ZYME?

Does the media refer more to IMMX or ZYME?

Summary

How does Immix Biopharma compare to ANI Pharmaceuticals?

Does the media prefer ANIP or IMMX?

Which has more volatility & risk, ANIP or IMMX?

Do insiders and institutionals have more ownership in ANIP or IMMX?

Which has higher earnings and valuation, ANIP or IMMX?

Is ANIP or IMMX more profitable?

Do analysts rate ANIP or IMMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools